BioMark Diagnostics (20B) Financial Statements
BioMark Diagnostics Financial Overview
BioMark Diagnostics's market cap is currently $31.96M. The company's EPS TTM is $-0.01; its P/E ratio is -34.81; BioMark Diagnostics has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 26 | Jun 25 | Jun 24 | Jun 22 | Jun 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 59.79K | $ 154.22K | $ 163.22K | $ 43.93K | $ 0.00 |
| Gross Profit | $ -322.49K | $ 154.22K | $ 163.22K | $ 43.93K | $ -13.69K |
| Operating Income | $ -1.87M | $ -1.91M | $ -1.32M | $ -1.28M | $ -1.09M |
| EBITDA | $ -1.49M | $ -1.46M | $ -919.05K | $ -1.22M | $ -1.08M |
| Net Income | $ -1.48M | $ -1.93M | $ -1.43M | $ -1.45M | $ -1.09M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.01M | $ 2.48M | $ 156.75K | $ 382.71K | $ 877.68K |
| Total Assets | $ 1.86M | $ 3.13M | $ 1.09M | $ 1.47M | $ 952.94K |
| Total Debt | $ 724.86K | $ 454.16K | $ 1.55M | $ 1.05M | $ 119.32K |
| Net Debt | $ 105.76K | $ -2.03M | $ 1.39M | $ 666.69K | $ -758.35K |
| Total Liabilities | $ 1.53M | $ 1.39M | $ 1.70M | $ 2.11M | $ 1.03M |
| Stockholders' Equity | $ 331.06K | $ 1.74M | $ -609.61K | $ -635.69K | $ -79.09K |
| Cash Flow | |||||
| Free Cash Flow | $ -1.09M | $ -1.10M | $ -986.91K | $ -1.26M | $ -455.55K |
| Operating Cash Flow | $ -1.09M | $ -1.09M | $ -982.52K | $ -1.20M | $ -455.55K |
| Investing Cash Flow | $ -396.05K | $ -3.53K | $ -4.39K | $ -59.20K | $ -3.20K |
| Financing Cash Flow | $ -377.83K | $ 3.42M | $ 1.07M | $ 768.16K | $ 724.63K |
Currency in CAD